CJC-1295 vs CJC-1295 with DAC
Side-by-Side Comparison
| Attribute | Cjc 1295 | Cjc 1295 Dac |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | CJC-1295 DAC binds to GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase via Gs coupling and increasing cAMP. This stimulates GH synthesis and release. |
| Evidence Rating | D — Preclinical | C — Phase I-II data; research compound |
| Clinical Status | Research-only / Not approved for human use | Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Water retention and edema reported, particularly facial puffiness; Numbness and tingling in extremities |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 1-2 mg per injection |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 1-2x per week |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~3647 g/mol (peptide) + DAC linker |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~8 days |
Overview
CJC-1295 and CJC-1295 with DAC are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
CJC-1295 with DAC — Mechanism & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone-releasing hormone (GHRH) analog with a unique lysine-linked maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo. This albumin binding extends the half-life from minutes (native GHRH) to approximately 8 days, allowing once- or twice-weekly dosing while maintaining sustained GH elevation. Unlike CJC-1295 without DAC (which preserves pulsatile GH release), the DAC version produces a continuous GH elevation pattern. This is both its advantage (convenience) and disadvantage (non-physiological GH pattern).
Key claims: Sustained growth hormone elevation; Convenient weekly dosing schedule; Improved body composition.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
CJC-1295 with DAC is also researched for: Growth Hormone, Recovery.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
CJC-1295 with DAC: Water retention and edema reported, particularly facial puffiness Numbness and tingling in extremities Joint pain consistent with GH elevation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.